Umeda Masahiro, Komatsubara Hideki, Ojima Yasutaka, Minamikawa Tsutomu, Shigeta Takashi, Shibuya Yasuyuki, Yokoo Satoshi, Komori Takahide
Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
Kobe J Med Sci. 2004;50(5-6):189-96.
Cisplatin-based neoadjuvant chemotherapy (NAC) has been reported to increase survival of patients with nasopharyngeal carcinoma, and organ preservation in those with laryngeal carcinoma, but its efficacy for other head and neck carcinomas is still controversial. We examined the effects of NAC for patients with stage III-IV squamous cell carcinoma of the oral cavity. The patients were divided into two groups; 9 patients who underwent NAC consisting of one course of cisplatin (CDDP), docetaxel (TXT) and 5-fluorouracil (5FU) followed by surgery (NAC group), and 18 patients who underwent surgery alone (control group). Complete response (CR) was not observed, but partial response (PR) was obtained in 6 of 9 patients (33%) of the NAC group. The 3-year survival rate was 29.6% in the NAC group and 81.5% in the control group. Although any valid conclusions could not be drawn because of the small number of patients examined here, NAC with CDDP, TXT and 5FU offered no advantages over standard treatment for advanced oral cancer in terms of survival.
据报道，基于顺铂的新辅助化疗（NAC）可提高鼻咽癌患者的生存率，并使喉癌患者能够保留器官，但其对其他头颈癌的疗效仍存在争议。我们研究了NAC对III-IV期口腔鳞状细胞癌患者的影响。患者分为两组；9例患者接受了由一个疗程的顺铂（CDDP）、多西他赛（TXT）和5-氟尿嘧啶（5FU）组成的NAC治疗，随后进行手术（NAC组），18例患者仅接受手术（对照组）。未观察到完全缓解（CR），但NAC组9例患者中有6例（33%）获得部分缓解（PR）。NAC组的3年生存率为29.6%，对照组为81.5%。尽管由于此处研究的患者数量较少无法得出任何有效结论，但就生存率而言，使用CDDP、TXT和5FU的NAC与晚期口腔癌的标准治疗相比并无优势。
